Pfizer, a biopharmaceutical company, agreed to invest $185m in BioNTech, a manufacturer of active immunotherapies. “We have already started working with Pfizer on our COVID-19 vaccine and are pleased to announce these further details of our ongoing collaboration, which reflects both companies’ strong commitment to move quickly to bring a safe and efficacious vaccine to patients worldwide,” Ugur Sahin, BioNTech Co-Founder and CEO.